Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Challenge Dose in Adults (V232-059-10)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In general good health based on a medical history.~* Received 3 doses of an Hepatitis B vaccine in Base Study V232-059, NCT00440531 at least 2 years prior to enrollment in this study.~Exclusion Criteria:~* Known history of previous Hepatitis B infection.~* History of vaccination with any Hepatitis B vaccine within the last 2 years.~* History of febrile illness.~* Known or suspected hypersensitivity to any component of HBVaxPro.~* Receipt of medication / vaccine that may interfere with study assessments.~* Known or suspected immune impairment.~* Pregnant women and nursing mothers.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Modified Process Hepatitis B Vaccine in Base Study (Type: EXPERIMENTAL): Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
- ENGERIX-B™ Vaccine in Base Study (Type: EXPERIMENTAL): Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study

Based on this trial design, predict the completion outcome and termination type (if applicable).